Replies to post #374576 on NorthWest Biotherapeutics Inc (NWBO)

[spartex]

Important question on what will happen with the eventual TLD results.

It is very clear from the blended results reported by LL (using youtube link to LL 2019 presentation provided by Nick), that DCVax-L is much more efficacious for the methylated subgroup (49% survival at 3 years, versus ~18% for non-methylated).

However, even presenting all subgroup results together may show statistical significance versus SOC for OS.

However, looking at the value of DCVax-L in terms of where it is most efficacious, will the industry (FDA and health care companies) give greater support to use of this therapy primarily for the methylated subgroup patients (get insurance coverage)?? Will they support it's use for the non-methylated subgroup?

Further out question, how long will it take for NWBO to resolve the reasons/ways to make DCVax-L more efficacious for the non-methylated groups?

I realize any response to these questions is difficult to do with limited information.

THanks!